STOCK TITAN

Taysha Gene Therapies, Inc. (TSHA) Net Income by Year

TSHA

Taysha Gene Therapies, Inc. reported a net loss of $109.0M in fiscal year 2025. This represents a decrease of 22.1% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Taysha Gene Therapies, Inc. has filed alongside them.

FY2025 annual
Net Income -$109.0M
YoY -22.1%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

TSHA Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
Net Income-$109.0M-22.1%-$89.3M+20.0%-$111.6M+32.8%-$166.0M+4.9%-$174.5M-190.8%-$60.0M

TSHA Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$46.6M-73.5%-$42.4M-97.0%N/A-$32.7M-28.2%-$26.9M-28.4%-$21.5M+10.5%-$18.8M-139.3%-$25.5M+78.2%-$20.9M+14.9%-$24.1M-36.5%$47.7M-$117.1M-341.4%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Taysha Gene Therapies, Inc. financials

Frequently Asked Questions

What was Taysha Gene Therapies, Inc.'s net income in fiscal year 2025?

Taysha Gene Therapies, Inc. reported a net loss of $109.0M in fiscal year 2025.

How fast is Taysha Gene Therapies, Inc.'s net income growing?

Taysha Gene Therapies, Inc. (TSHA) net income fell by 22.1% year over year, from -$89.3M to -$109.0M in fiscal year 2025.

How has Taysha Gene Therapies, Inc.'s net income changed over the years?

Across the 6 fiscal years this page covers, Taysha Gene Therapies, Inc. (TSHA) net income went from -$60.0M in fiscal year 2020 to -$109.0M in fiscal year 2025.

Taysha Gene Therapies, Inc. (TSHA) reported -$46.6M in net income in Q2 2026. This represents a decrease of 73.5% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Taysha Gene Therapies, Inc. (TSHA) reported on that line in every period on record.